Payment overview · 2025
General Payments
$852.67
38 reported records · 14 companies
Healthcare provider profile · identity verified
Anthony Peter Macarthy, M.D
Allopathic & Osteopathic Physicians|Family Medicine · SILVER SPRING, MD · NPI 1629300470
Verified facts
What the public records show
CMS Open Payments records show Anthony Peter Macarthy, M.D received $852.67 in general payments during 2025 across 38 reported records.
Lilly USA, LLC accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $204.44 | 24.0% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $121.46 | 14.2% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $111.02 | 13.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.98 | 10.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.90 | 10.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.14 | 5.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $41.57 | 4.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.27 | 4.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.30 | 3.1% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.60 | 2.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.79 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.12 | 1.9% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $16.03 | 1.9% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $14.05 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $852.67 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $175.37 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $146.97 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $137.32 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $89.87 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $86.98 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $86.98 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $85.90 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.90 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.14 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $41.57 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.27 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.59 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Scientific Affairs, LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 142 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 53 |
| Metformin Hcl | Metformin Hcl | 209 | 51 |
| Trazodone Hcl | Trazodone Hcl | 173 | 32 |
| Eliquis | Apixaban | 142 | 17 |
| Simvastatin | Simvastatin | 141 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 133 | 21 |
| Mirtazapine | Mirtazapine | 132 | 20 |
| Donepezil Hcl | Donepezil Hcl | 129 | 17 |
| Gabapentin | Gabapentin | 125 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 116 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 26 |
| Lisinopril | Lisinopril | 111 | 23 |
| Omeprazole | Omeprazole | 108 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 24 |
| Losartan Potassium | Losartan Potassium | 103 | 29 |
| Furosemide | Furosemide | 102 | 15 |
| Famotidine | Famotidine | 97 | 13 |
| Mupirocin | Mupirocin | 92 | 37 |
| Potassium Chloride | Potassium Chloride | 89 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 12 |
| Montelukast Sodium | Montelukast Sodium | 79 | 17 |
| Glipizide | Glipizide | 78 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 60 |
| Carvedilol | Carvedilol | 74 | 11 |
| Divalproex Sodium | Divalproex Sodium | 65 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 60 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 59 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 19 |
| Metolazone | Metolazone | 59 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | suppressed |
| Risperidone | Risperidone | 50 | suppressed |
| Allopurinol | Allopurinol | 48 | suppressed |
| Azithromycin | Azithromycin | 48 | 41 |
| Olanzapine | Olanzapine | 48 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | suppressed |
| Latanoprost | Latanoprost | 46 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | suppressed |
| Eszopiclone | Eszopiclone | 43 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 11 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Metronidazole | Metronidazole | 28 | 17 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | 14 |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Desloratadine | Desloratadine | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | 13 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Methocarbamol | Methocarbamol | 20 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Perphenazine | Perphenazine | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $852.67 · 38 records | Lilly USA, LLC | APTIMA, AREXVY, CAPLYTA, Cologuard Collection Kit, ELIQUIS, INVEGA SUSTENNA, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, ZEPBOUND, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error